

PSMA PET/CT for Initial Staging

PATIENT CASE STUDY 01

Patient overview:

- 70 y/o male with newly diagnosed prostate cancer, Gleason 4+4, PSA 5.28 ng/ml.
- PSMA PET/CT ordered to initially stage the patient to improve the sensitivity of anatomical-based imaging.

Impact of PSMA PET/CT:

- Focal intense uptake was noted in the prostate bed with no nodal uptake noted.
- Solitary rib uptake with associated sclerosis (fibrous uptake).
- The solitary rib uptake should not preclude definitive management, especially in the setting of absent nodal uptake.

PSMA PET/CT images:



PSMA PET/CT for Recurrence (Biochemical failure)

PATIENT CASE STUDY 02


Patient overview:

- 68 y/o patient with a history of group grade 3 prostate cancer s/p prostatectomy and now with asymptomatic biochemical failure with PSA or 1.0 ng/ml.
- Negative CT and mpMRI of the pelvis.

Impact of PSMA PET/CT:

- Positive study with nodes outside the pelvis. Risk stratified away from futile salvage radiation therapy.
- Placed on systemic therapy.

PSMA PET/CT images:



PYLARIFY (PIFLUFOLASTAT F18)

PYLARIFY, the imaging agent for PSMA, is the only commercial agent with FDA approval for staging in prostate cancer, making it the preferred choice.